Akademik Veri Yönetim Sistemi
The 13th International Symposium on Pharmaceutical Sciences (ISOPS) , Ankara, Türkiye, 22 - 25 Haziran 2021, cilt.1, sa.1, ss.69
Introduction: Treatment of breast cancer using
doxorubicin (DOX), a potent antitumoral drug, is
broadly considered one of the most common
treatment modalities. However, the cytotoxic
effects of the DOX significantly restrict its use, and
also the development of resistance to DOX is
frequently seen. Therefore, the combination
therapies of DOX with different compounds and
molecules to overcome drug resistance and
minimize cytotoxic effect appears to be more
promising in cancer cells (1). Melatonin (MEL) is a
hormone secreted from the pineal gland and has
an anti-proliferative effect on various tumor types
(2). While many cancer studies on MEL are used
as an adjuvant with chemotherapeutic drugs, no
research in this direction has been found regarding
agomelatine (AGO), which is MT1/MT2 melatonin
receptor agonist. With the aim of developing a new
adjuvant therapy, the present study tested the
effects of AGO alone or combined with DOX on
breast cancer.
Materials and Methods: The effects of DOX,
MEL, AGO, and their combinations (DOX+MEL
and DOX+AGO) were investigated on the
proliferation in the MCF-7 cells. The MCF-7 cells
were separated into the following six groups:
Control, DOX, MEL, AGO, DOX+MEL and
DOX+AGO. Cell viability was determined by the 3-
(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) assay. The cells were exposed to
appropriate nontoxic concentrations and
incubation times for AGO by assessing cell viability
in cell culture. Then cells were incubated with DOX,
MEL, and AGO for 24 h.